

## Skyrizi IV Order Form (risankizumab-rzaa)

FAX TO: 972.499.9210

PATIENT INFORMATION					
Patient Name:	DOB:	Phone:	Sex: M F Ht:	Wt: lbs kg	
Primary Language:	Allergies:				
Patient Preferred Loca	tion:				
<icd 10="" code="" required=""> DIAGNOSIS &amp; CLINICAL INFORMATION</icd>					
K50.1 Cro K50.8 Cro	hn's Disease, Small Intestine hn's Disease, Large Intestine hn's Disease, Small and Large Intestine hn's Disease, Unspecified	K51.01 K51.90	Ulcerative Colitis, Unspecific Ulcerative (Chronic) Pancoli Ulcerative Colitis, Unspecific Ulcerative (Chronic) Pancoli Complications	tis with Complications ed, without Complications	
<u>REQUIRED</u> : Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. <u>LAB RESULTS</u> : Include Negative TB within 12 months.					
PRESCRIPTION					
SKYRIZI IV (risankizumab-rzaa)  Loading Dose IV Infuse 600 mg in 250 ml of 5% Dextrose over at least 1 hour at weeks 0, 4, and 8		+Medix Infusion	Lab Orders+  Required: Negative TB, Liver enzymes and bilirubin at weeks 0 and 4  +Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider		
Is the patient on any other disease modifying therapy? Yes No If yes, please note therapy and last dose:					
Post Treatment Observations: The patient is observed for 30 minutes following the first administration.					
Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.					
Comments:					
<u></u>					
PRESCRIBER INFORMATION					
Prescriber Name:		Signature:			
	_ NPI #:	_			
Address:	City:		State:	Zip:	
Contact Name:	Phone:	Fax:	Email:		